Knock-out of CD37 enhanced the lipid storage capacity in DLBCL cells, which lead to an increased dependence of cells on FA-metabolic switch.[32] Targeted disruption of CD37-FA transporter protein 1 interaction using metabolic inhibitors may decrease survival and proliferation of DLBCL (Fig. 1). The gene discussed is CD37; the disease is diffuse large B-cell lymphoma.